TISIDB

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Chromosome, centromere Chromosome, centromere, kinetochore Cytoplasm, cytoskeleton, spindle pole Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Note=Localizes to the inner centromere throughout prophase until metaphase and disappears at anaphase (PubMed:16541025). Centromeric localization requires the presence of BUB1 and the interaction with PPP2R1A (PubMed:16580887)(PubMed:16541025)(PubMed:15604152). Colocalizes with NEK2 at the kinetochore (PubMed:17621308). Colocalizes with and SS18L1 at the kinetochore (PubMed:16582621). Phosphorylation by AUKRB and the presence of BUB1 are required for localization to the kinetochore (PubMed:17617734). Isoform 1 primarily localizes to kinetochores during G2 phase and mitotic prophase, metaphase, and anaphase and does not appear to be associated with kinetochores during late mitosis (PubMed:16582621). Isoform 3 is found at the centrosome in interphase and at spindle poles in mitosis and its spindle pole localization is PLK1 dependent (PubMed:16582621). Isoform 3 does not localize to kinetochores during any stages of the cell cycle (PubMed:16582621).
Domain	PF07557 Shugoshin C terminus PF07558 Shugoshin N-terminal coiled-coil region
Function	Plays a central role in chromosome cohesion during mitosis by preventing premature dissociation of cohesin complex from centromeres after prophase, when most of cohesin complex dissociates from chromosomes arms. May act by preventing phosphorylation of the STAG2 subunit of cohesin complex at the centromere, ensuring cohesin persistence at centromere until cohesin cleavage by ESPL1/separase at anaphase. Essential for proper chromosome segregation during mitosis and this function requires interaction with PPP2R1A. Its phosphorylated form is necessary for chromosome congression and for the proper attachment of spindle microtubule to the kinetochore. Necessary for kinetochore localization of PLK1 and CENPF. May play a role in the tension sensing mechanism of the spindle-assembly checkpoint by regulating PLK1 kinetochore affinity. Isoform 3 plays a role in maintaining centriole cohesion involved in controlling spindle pole integrity. Involved in centromeric enrichment of AUKRB in prometaphase.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0000819 sister chromatid segregation GO:0007059 chromosome segregation GO:0007062 sister chromatid cohesion GO:0007067 mitotic nuclear division GO:0007126 meiotic nuclear division GO:0008608 attachment of spindle microtubules to kinetochore GO:0010457 centriole-centriole cohesion GO:0031023 microtubule organizing center organization GO:0045132 meiotic chromosome segregation GO:0051297 centrosome organization GO:0051321 meiotic cell cycle GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process
Molecular Function	-
Cellular Component	GO:0000775 chromosome, centromeric region GO:0000776 kinetochore GO:0000777 condensed chromosome kinetochore GO:0000779 condensed chromosome, centromeric region GO:0000780 condensed nuclear chromosome, centromeric region GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0000922 spindle pole GO:0005813 centrosome GO:0005819 spindle GO:0044454 nuclear chromosome part GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04114 Oocyte meiosis
Reactome	-

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SGOL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SGOL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SGOL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.385	0.193
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.086	0.909
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.618	0.414
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.377	0.459
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.55	0.677
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.152	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.018	0.956
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.38	0.649
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.495	0.533
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.73	0.243
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.681	0.404
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.698	5.04e-07

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SGOL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SGOL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SGOL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SGOL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SGOL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SGOL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SGOL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SGOL1
Name	shugoshin-like 1 (S. pombe)
Aliases	NY-BR-85; CAID; SGO; Sgo1; serologically defined breast cancer antigen NY-BR-85; shugoshin 1AB protein; shug ......
Chromosomal Location	3p24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SGOL1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SGOL1